MarketCap
Facebook
X
TelegramQuartalsbericht 2026-Q1
hinzugefügt 07.05.2026
Rockwell Medical Langfristiger Schuldenstrom 2011-2026 | RMTI
Langfristiger Schuldenstrom Jährlich Rockwell Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 M | 1.57 M | 1.38 M | 1.48 M | 7.38 M | - | 1.49 M | - | - | - | - | - | 2.31 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.38 M | 1.16 M | 2.4 M |
Langfristiger Schuldenstrom anderer Aktien in der Arzneimittelhersteller
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
468 K | $ 5.91 | 0.68 % | $ 87.8 M |  USA |
 |
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
59.5 K | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
12.5 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
100 K | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
1.08 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
337 K | $ 2.74 | -0.18 % | $ 1.05 B | Canada |
 |
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
887 K | $ 33.69 | 2.09 % | $ 1.24 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
8.89 M | $ 24.21 | 3.68 % | $ 1.12 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
61 M | $ 5.38 | -1.74 % | $ 2 B | Canada |
 |
Organogenesis Holdings
ORGO
|
4.95 M | $ 2.64 | -0.75 % | $ 335 M | USA |
 |
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.04 | - | $ 112 M | Canada |
 |
Solid Biosciences
SLDB
|
2.1 M | $ 6.89 | 4.08 % | $ 603 M | USA |
 |
Aurora Cannabis
ACB
|
5.38 M | $ 3.45 | -0.35 % | $ 189 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 1.07 | -2.73 % | $ 1.33 M | USA |
 |
Jupiter Wellness
JUPW
|
23.5 K | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
2.47 M | $ 5.41 | 2.17 % | $ 3.34 B | Canada |
 |
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
1.03 M | $ 1.12 | -0.45 % | $ 107 M | Canada |
 |
Evolus
EOLS
|
2.53 M | $ 6.21 | 1.89 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
35.5 M | $ 1.45 | - | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
2.4 M | $ 9.13 | 8.05 % | $ 488 M | USA |
 |
Veru
VERU
|
759 K | $ 2.3 | -2.13 % | $ 33.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.05 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
240 K | $ 23.44 | - | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
778 K | $ 0.76 | -0.28 % | $ 3.06 M | USA |
 |
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
483 K | $ 0.7 | -4.14 % | $ 35 M | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
109 M | $ 16.33 | -1.92 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
71.6 K | $ 0.78 | 2.67 % | $ 3.35 M |  China |
 |
TherapeuticsMD
TXMD
|
975 K | $ 2.12 | - | $ 24.5 M | USA |